MRNA
Moderna, Inc.
There isn't enough reported data to score MRNA yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
MRNA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
MRNA's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
MRNA PE Valuation
MRNA has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
MRNA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect MRNA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
MRNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$7.09 | +$0.98 |
| Q2 2026 | -$7.98 | -$0.45 |
| Q1 2026 | -$8.14 | +$0.59 |
| Q4 2025 | -$7.26 | +$2.02 |
| Q3 2025 | -$8.07 | -$2.33 |
| Q2 2025 | -$7.53 | +$7.77 |
| Q1 2025 | -$8.73 | +$6.86 |
| Q4 2024 | -$9.28 | +$3.05 |
MRNA is still losing money, but far less than before: $7.09 per share over the past year, against $15.59 at its worst in early 2024.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over MRNA on earnings quality, reporting a profit while its opponent remains loss making.
MRNA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.3B | +29% |
| Q2 2026 | $145M | +2.1% |
| Q1 2026 | $389M | +260% |
| Q4 2025 | $678M | -30% |
| Q3 2025 | $1B | -45% |
| Q2 2025 | $142M | -41% |
| Q1 2025 | $108M | -35% |
| Q4 2024 | $966M | -66% |
MRNA's revenue is recovering but still below its 2021 peak: $1.3B last quarter, up 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.9% | +36 points |
| Q2 2026 | -562% | +77 points |
| Q1 2026 | -357% | +615 points |
| Q4 2025 | -126% | +2.6 points |
| Q3 2025 | -26% | -22 points |
| Q2 2025 | -639% | -73 points |
| Q1 2025 | -972% | -214 points |
| Q4 2024 | -129% | -129 points |
MRNA has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over MRNA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
MRNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$726M |
| Q2 2026 | -$563M | +$359M |
| Q1 2026 | -$692M | +$462M |
| Q4 2025 | $891M | +194% |
| Q3 2025 | -$880M | +$837M |
| Q2 2025 | -$922M | +$534M |
| Q1 2025 | -$1.2B | +$31M |
| Q4 2024 | $303M | -25% |
MRNA has burned cash in six of the last eight quarters: −$2B over the past year, against −$2.7B the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over MRNA on cash generation, producing positive trailing cash flow while its opponent burns cash.
MRNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8% | +32M shares |
| 1 year | +10% | +40M shares |
| 3 years | +13% | +49M shares |
| 5 years | -0.9% | -4M shares |
| Available history | +30% | +99.2M shares |
MRNA has 430M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $1M |
| Q2 2023 | $628M |
| Q1 2023 | $526M |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over MRNA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
MRNA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2023 | -4.4x | Net Cash |
| Q1 2023 | -0.7x | Net Cash |
| Q4 2022 | -0.3x | Net Cash |
| Q3 2022 | -0.2x | Net Cash |
| Q2 2022 | -0.2x | Net Cash |
| Q1 2022 | -0.3x | Net Cash |
| Q4 2021 | -0.5x | Net Cash |
| Q3 2021 | -0.7x | Net Cash |
MRNA has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
MRNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.5 | Overbought |
| Stochastic | 85.1 | Overbought |
MRNA's weekly RSI is 71 (overbought) and its Stochastic is 85 (overbought).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
MRNA PE vs Healthcare Sector
| Metric | MRNA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MRNA has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
MRNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $217.4 | 6.4% above |
| 20 week MA | $145.4 | 59% above |
| 50 week MA | $86.0 | 169% above |
| 100 week MA | $57.8 | 300% above |
| 200 week MA | $82.4 | 181% above |
MRNA has the edge over UNH on trend strength, trading above more of its moving averages.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
MRNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.5 | $123.4 | +532% |
| 2021 | $123.4 | $250.0 | +103% |
| 2022 | $250.0 | $199.1 | -20% |
| 2023 | $199.1 | $99.5 | -50% |
| 2024 | $99.5 | $40.1 | -60% |
| 2025 | $40.1 | $31.2 | -22% |
| 2026 YTD | $31.2 | $231.4 | +642% |
MRNA has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.